Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II study of FP-101 recruiting participants

April 9, 2018

Phase II ATOMIK study of serlopitant does not meet primary or key secondary efficacy endpoints

April 9, 2018

Recordati acquires rights to Cystagon

April 9, 2018

Enrollment ongoing in phase I trial of NGM-120

April 9, 2018

DGKB biomarker tied to antipsychotic therapy-induced weight gain

April 9, 2018

Bayer enrolling participants in phase I trial of BAY-2402234

April 9, 2018

FDA grants approval for Rubraca as maintenance treatment of recurrent ovarian cancer

April 9, 2018

FDA accepts NDA for duvelisib

April 9, 2018

Protocadherin-23 tied to adverse prognostic factors in breast cancer

April 9, 2018

Pivotal phase III ECHO-301/KEYNOTE-252 study of epacadostat does not meet primary endpoint

April 9, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...